Advances in Biostatistics: Estimators Based on Misspecified Models and Predictions of Survival Times

生物统计学的进展：基于错误指定模型和生存时间预测的估计器

• 批准号: RGPIN-2018-04304
• 负责人: Altman, Rachel
• 金额: $ 1.31万
• 依托单位: Simon Fraser University
• 依托单位国家: 加拿大
• 项目类别: Discovery Grants Program - Individual
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=676831
• 关键词: Advances; Biostatistics; Estimators; Based; Misspecified

My proposed research program has two themes: The development and study of simple estimators of complex models, and the prediction of survival times. Such methods are of particular importance in biostatistics, and will have impact on subject areas including rainfall modelling, multiple sclerosis, and ovarian cancer.******With respect to the first theme, I plan to work in the context of time series of rainfall observations, which are complicated to describe because they take on both continuous and zero values, and are correlated over time. Estimation of the effects of factors that influence rainfall can thus be challenging. I intend to investigate the performance of an estimator that assumes that the observations are, in fact, uncorrelated. Earlier work with count data suggests that such an estimator could be well-behaved, efficient, and simpler to compute than previously considered estimators. I will evaluate the properties of this estimator, and will apply my results to the problem of estimating time trends and the Oceanic Nio Index (“El Nio”) effect on rainfall in Costa Rica. I also plan to work in the context of multiple sclerosis (MS) clinical trials where the outcome is the number of lesions detected using MRI scans of patients' brains over the course of the study period, and where patients were selected for lesion activity at baseline (a so-called “enrichment” study design). Previous authors propose a naive estimator of the effect of treatment that ignores the patient selection process. I will study the performance of an alternative estimator that can be computed with little effort, yet performs better than the nave estimator. My work will allow for improved estimation of the treatment effect and for better planning of sample sizes in enriched MS trials. I will subsequently extend our methods to other types of responses collected in enriched trials.******My second theme concerns the prediction of recurrence and death times of ovarian cancer patients. Our initial work has shown that random survival forests are a useful tool for predicting either recurrence or death times; I plan to extend these methods to allow for their simultaneous prediction. In addition, I will develop prediction intervals for survival times that allow the quantification of our uncertainty about our predictions. One challenge is that the prediction of the survival time of a patient with a low expected survival time is inherently an easier problem than the prediction of the survival time of a patient with a high expected survival time. I thus intend to develop methods for identifying subgroups of patients for whom relatively precise predictions can be computed. Ultimately, my collaborators and I hope to develop an online decision support tool that patients and their caregivers can use to guide the management of ovarian cancer risks.

我提出的研究计划有两个主题：复杂模型的简单估计的发展和研究，以及生存时间的预测。这种方法在生物统计学中特别重要，并将对降雨建模，多发性硬化症和卵巢癌等学科领域产生影响。关于第一个主题，我计划在降雨观测时间序列的背景下工作，这是复杂的描述，因为它们采取连续和零值，并随着时间的推移相关。因此，估计影响降雨的因素的影响可能具有挑战性。我打算研究假设观测值实际上不相关的估计器的性能。计数数据的早期工作表明，这样的估计量可能是行为良好的，有效的，并且比以前考虑的估计量更容易计算。我将评估这个估计的属性，并将我的结果估计时间趋势和海洋厄尔尼诺指数（“厄尔尼诺”）对降雨的影响在哥斯达黎加的问题。我还计划在多发性硬化症（MS）临床试验的背景下工作，其结果是在研究期间使用MRI扫描患者大脑检测到的病变数量，并且患者在基线时被选择为病变活动（所谓的“富集”研究设计）。以前的作者提出了一个天真的估计治疗的效果，忽略了病人的选择过程。我将研究另一种估计器的性能，这种估计器可以很容易地计算出来，但比朴素估计器性能更好。我的工作将允许改善估计的治疗效果和更好地规划的样本量在丰富的MS试验。随后，我将把我们的方法扩展到在丰富试验中收集的其他类型的反应。我的第二个主题是关于预测卵巢癌患者的复发和死亡时间。我们最初的工作表明，随机生存森林是预测复发时间或死亡时间的有用工具;我计划扩展这些方法以允许它们同时预测。此外，我将开发生存时间的预测区间，以量化我们对预测的不确定性。一个挑战是，预测具有低预期存活时间的患者的存活时间本质上是比预测具有高预期存活时间的患者的存活时间更容易的问题。因此，我打算开发一些方法来确定可以计算出相对精确预测的患者亚组。最终，我和我的合作者希望开发一种在线决策支持工具，患者及其护理人员可以使用该工具来指导卵巢癌风险的管理。